OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Milei Threatens Falkland Oil Firms With Sanctions 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
SEATTLE, Feb. 27, 2018 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual ROTH Conference on Tuesday March 13th, 2018 at 12:00 p.m. PT at the Ritz Carlton, Laguna Niguel, California.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases. Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
